Flagship Harbor Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Flagship Harbor Advisors’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-94	Closed	-$9K	–	1888
2020 Q3	$9K	Hold	94	–	–	﹤0.01%	1376
2020 Q2	$14K	Hold	94	–	–	﹤0.01%	1258
2020 Q1	$14K	Hold	94	–	–	﹤0.01%	1145
2019 Q4	$19K	Buy	94 +24	+34%	+$4.38K	﹤0.01%	1134
2019 Q3	$5K	Hold	70	–	–	﹤0.01%	1518
2019 Q2	$6K	Buy	+70	New	+$6.04K	﹤0.01%	1471

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Flagship Harbor Advisors's RETA Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2020, closing a stake of 94 shares — an estimated $9K sold.

Flagship Harbor Advisors first reported a position in RETA in Q2 2019 and held it in 6 quarters. The position peaked at $19K in Q4 2019. 202 funds tracked by Wall St. Rank hold RETA as of Q4 2020.

Flagship Harbor Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2020 after selling out during the quarter.
Flagship Harbor Advisors sold 94 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2020, an estimated $9K.
Flagship Harbor Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 6 quarters.
Flagship Harbor Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $19K in Q4 2019.
202 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.